药企支付与医生处方品牌鼻用糖皮质激素的关联
这项横断面回顾性分析链接了2014-2015年 Medicare 处方数据与药企支付数据,覆盖164,587名开具鼻用糖皮质激素的医生。结果显示,接受 Dymista 或 Nasonex 支付的医生开具相应品牌药的比例显著高于未接受支付者,且支付次数和金额与品牌药处方频率相关。
要点
- 接受 Dymista 支付的医生其 Dymista 处方占比为3.1%,未接受者为0.2%(P<.001)。
- 接受 Nasonex 支付的医生其 Nasonex 处方占比为12.0%,未接受者为4.8%(P<.001)。
- Dymista 的支付与处方关联在耳鼻咽喉科医生中强于全科医生。
核心结论
- 药企对品牌鼻用糖皮质激素的支付与医生处方模式显著相关。
- 关联强度可能取决于医生专科和药物上市时间。
研究设计与样本
- 横断面回顾性分析,全国范围。
- 识别2014-2015年向 Medicare 受益人开具鼻用糖皮质激素的医生,并链接药企支付数据。
- 共纳入164,587名医生,其中耳鼻咽喉科医生7,937名(5%)。
- 分别有10,800名和3,886名医生接受 Dymista 和 Nasonex 的药企支付。
主要发现
- 接受 Dymista 支付的医生开具 Dymista 占其鼻用糖皮质激素处方的比例高于未接受支付者(3.1% [SD=9.6%] vs 0.2% [SD=2.5%],P<.001)。
- 接受 Nasonex 支付的医生开具 Nasonex 的比例高于未接受支付者(12.0% [SD=16.8%] vs 4.8% [SD=13.6%],P<.001)。
- 支付次数和金额与 Dymista 处方频率相关(ρ=0.26,P<.001;ρ=0.20,P<.001)。
- 支付次数和金额与 Nasonex 处方频率相关(ρ=0.09,P<.001;ρ=0.15,P<.001)。
- Dymista 的支付与处方关联在耳鼻咽喉科医生中强于全科医生(P<.001)。
关键数值与推荐
- 接受 Dymista 支付者 Dymista 处方占比3.1%(SD=9.6%),未接受者0.2%(SD=2.5%),P<.001。
- 接受 Nasonex 支付者 Nasonex 处方占比12.0%(SD=16.8%),未接受者4.8%(SD=13.6%),P<.001。
- Dymista 支付次数与处方频率的相关系数 ρ=0.26(P<.001),支付金额与处方频率的相关系数 ρ=0.20(P<.001)。
- Nasonex 支付次数与处方频率的相关系数 ρ=0.09(P<.001),支付金额与处方频率的相关系数 ρ=0.15(P<.001)。
临床怎么用
- 临床医生应意识到药企支付可能与品牌鼻用糖皮质激素处方倾向相关。
- 耳鼻咽喉科医生接受 Dymista 支付时,其品牌药处方占比更高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objectives To examine the association of industry payments for brand-name intranasal corticosteroids with prescribing patterns. Study Design Cross-sectional retrospective analysis. Setting Nationwide. Subjects and Methods We identified physicians prescribing intranasal corticosteroids to Medicare beneficiaries 2014-2015 and physicians receiving payment for the brand-name intranasal corticosteroids Dymista and Nasonex. Prescription and payment data were linked by physician, and we compared the proportion of prescriptions written for brand-name intranasal corticosteroids in industry-compensated vs non-industry-compensated physicians. We associated the number and dollar amount of industry payments with the relative frequency of brand-name prescriptions. Results In total, 164,587 physicians prescribing intranasal corticosteroids were identified, including 7937 (5%) otolaryngologists; 10,800 and 3886 physicians received industry compensation for Dymista and Nasonex, respectively. Physicians receiving industry payment for Dymista prescribed more Dymista as a proportion of total intranasal corticosteroid prescriptions than noncompensated physicians (3.1% [SD = 9.6%] vs 0.2% [SD = 2.5%], respectively, P < .001). Similar trends were seen for Nasonex (12.0% [SD = 16.8%] vs 4.8% [SD = 13.6%], P < .001). The number and dollar amount of payment were significantly correlated to the relative frequency of Dymista (ρ = 0.26, P < .001 and ρ = 0.20, P < .001, respectively) and Nasonex prescriptions (ρ = 0.09, P < .001 and ρ = 0.15, P < .001, respectively). For Dymista, this association was stronger in otolaryngologists than general practitioners ( P < .001). There was a stronger correlation between the percentage of prescriptions and the number and dollar amount of payments for Dymista than for Nasonex ( P = .014 and P < .001). Conclusions Industry compensation for brand-name intranasal corticosteroids is significantly associated with prescribing patterns. The magnitude of association may depend on physician specialty and the drug's time on the market.
引用
- Morse E, Fujiwara RJT, Mehra S, et al. The Association of Industry Payments to Physicians with Prescription of Brand-Name Intranasal Corticosteroids. Otolaryngol Head Neck Surg. 2018. PMID: 29865931. doi:10.1177/0194599818774739
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。